Supercharged immune cells take aim at Tough-to-Treat cancers
NCT ID NCT06027983
Summary
This study is testing a new combination treatment for people with advanced HER2-positive cancers, including breast and stomach cancers. It combines a standard antibody drug (trastuzumab) with a patient's own immune cells that have been genetically engineered in a lab to better recognize and attack cancer. The first part checks if this combination is safe, and the second part expands to see if it helps control tumor growth in patients with advanced breast cancer who have already tried other treatments.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OTHER SOLID TUMORS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.